CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Core Viewpoint - CG Oncology, Inc. has successfully closed a public offering of 9,200,000 shares of common stock, raising gross proceeds of $238.0 million before expenses, aimed at advancing its bladder cancer therapeutic development [1]. Group 1: Offering Details - The public offering consisted of 9,200,000 shares, with 8,500,000 shares offered by CG Oncology and 700,000 shares by an existing stockholder [1]. - The offering price was set at$28.00 per share, which included the full exercise of the underwriters' option to purchase an additional 1,200,000 shares [1]. - The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions, amounted to $238.0 million [1]. Group 2: Underwriters and Management - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [2]. - LifeSci Capital LLC served as the lead manager for the offering [2]. Group 3: Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [5].